5-amino-1MQ

What 5-amino-1MQ does

5-amino-1MQ is a small molecule, not a peptide. People use it for fat loss and energy, but controlled benefits come from animals and cells. No human dosing or efficacy trial was found. A mixed-drug human harm report exists, and online product quality adds risk.

• In mice, it lowered weight and fat stores without a clear drop in how much they ate. (animal)
• In old mice, it improved muscle repair after injury, and in another mouse study grip strength improved. (animal)
• People report using it for fat loss and more energy, though some notice no effect; it has never been tested in human trials. (Reported by users)

Uses in the sources

• People report using it for fat loss. Mouse results do not establish weight loss in people. (Reported by users) (source)
• Users report more energy or no effect. No controlled human energy study was found. (Reported by users) (source)
• Used in body-composition stacks; muscle-function findings are from aged mice. (Reported by users) (source)

5-amino-1MQ dosage

Typical reported dose: 25 mg twice a day by mouth (50 mg a day)

• Oral 50 mg, split twice: 25 mg morning and 25 mg early afternoon twice daily; 50 mg total per day, by mouth. Reported by users, common report. Studied in: Adults in online community reports; product contents and outcomes unverified. (source)
• Oral guide: 50 then 75 mg: 50 mg daily for 1–2 weeks, then 75 mg daily if increased once daily, by mouth. Reported by users, occasional report. Studied in: Adults in online community reports; product contents and outcomes unverified. (source)
• Small injections: 500–1000 mcg: 500–1000 mcg under the skin daily once daily, under the skin. Reported by users, occasional report. Studied in: Adults in online community reports; product contents and outcomes unverified. (source)
• Daily 5 mg report: 5 mg under the skin each morning once daily in the morning, under the skin. Reported by users, occasional report. Studied in: Adults in online community reports; product contents and outcomes unverified. (source)
• Injection guide: 10–30 mg: 10–30 mg under the skin daily once daily, under the skin. Reported by users, occasional report. Studied in: Adults in online community reports; product contents and outcomes unverified. (source)
• High injection report: 100 mg: 100 mg under the skin daily once daily, under the skin. Reported by users, rare report. Studied in: Adults in online community reports; product contents and outcomes unverified. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix 5-amino-1MQ

Comes as: Community-reported oral capsules and loose powder, Community-reported powder vials and premixed injection blends.

Mixed with: Bacteriostatic water is reported online. There is no approved diluent or mixing instruction for human use..

Common vial sizes: 5, 10, 50 mg. Common water amounts: 1, 2, 3.5 mL.

• Reported examples include 10 mg/1 mL, 10 mg/2 mL and 50 mg/3.5 mL. These are community practices, not validated formulations.
• One dosing thread gives incorrect syringe-unit conversions. Syringe units measure volume, not milligrams.
• Iodide and chloride are different salt forms. A nominal milligram may refer to salt weight or active-molecule weight.
• Cooling, bacteriostatic water or a clear appearance cannot establish sterility. Do not use a cloudy, gelled or visibly changed injection.

Before mixing: Community advice says cool, dry and sealed. No validated product-specific temperature or shelf life was found.

After mixing: Community advice says refrigerate and protect from light. Potency, sterility and a safe use-by date after mixing are unknown.

5-amino-1MQ side effects and risks

Reported side effects

• Stomach upset or nausea: Community reports; no controlled human rate., moderate. Stop and seek review if symptoms persist. (source)
• Injection stinging or skin bumps: Anecdotal reports; no measured rate., mild. Persistent redness, warmth or swelling needs assessment. (source)
• Dull or blunted emotions: One oral use report, more noticeable with higher doses., moderate. Stop and discuss new mood changes with a clinician. (source)
• Sleepiness: Reported in oral users and after 3 mg subcutaneous; frequency unknown., moderate. Avoid driving when sleepy and review new symptoms. (source)
• Frequent urination: One oral 50 mg report; identity and cause were unconfirmed., moderate. New persistent thirst or urination needs medical review. (source)
• Illness after mixed injections: One teaching case; compound specific causation and rates are unknown., serious. Seek urgent care for systemic illness or dark/low urine. (source)

Stop and get help if

• Dark urine or much less urine, especially with vomiting or muscle pain: Stop use and get urgent medical assessment.
• Breathing trouble, throat swelling, collapse or severe chest symptoms after an injection: Call emergency services now.
• Fever, shaking chills, rapidly spreading redness or feeling very ill after injection: Seek urgent care for possible infection or a contaminated injection.

Who should avoid it

• pregnant: Avoid exposure. Pregnancy safety and fetal effects have not been established.
• breastfeeding: Avoid exposure. Transfer into milk and infant safety are unknown.
• tryingToConceive: Fertility effects and a safe interval before conception are unknown.
• under18: No pediatric dosing or safety study was found.
• kidneyDisease: Human clearance and dose adjustment are unknown; kidney-model benefits do not establish safety in kidney disease.
• liverDisease: Human liver safety and dose adjustment are unknown. Improved mouse liver tests do not establish human safety.
• diabetes: Mouse glucose effects raise a theoretical interaction concern with diabetes medicines; the human effect is unknown.
• heartCondition: Stressed blood-vessel cells had lower viability with NNMT inhibition; clinical heart effects are unknown.
• psychiatricCondition: Mood blunting is anecdotal. A lab MAO-A signal raises an untested medication-interaction concern.
• activeCancer: Cancer experiments are not human cancer treatment evidence. Review use with the oncology team.
• surgeryPlanned: Tell the surgical team about use; no evidence-based stop interval or anesthesia interaction study was found.
• testedAthlete: S0 covers unapproved pharmacological drugs at all times. Applying that rule here is a class-rule interpretation.

Interactions

• Insulin and sulfonylureas: Additive glucose lowering is theoretical from mouse findings. No human interaction study supports a medicine-dose change.
• Serotonergic medicines: Lab MAO-A inhibition raises an untested interaction concern. Whether human exposure affects serotonin is unknown.
• MAO inhibitors and stimulants: A lab MAO-A signal warrants medicine review. This is not proof that 5-amino-1MQ acts as a clinical MAOI.
• GLP-1-based medicines: Users combine them, but added benefit, tolerability and effects on oral-drug absorption have not been tested in humans.
• Anticoagulants and medicines needing close level control: No human interaction study was found. Effects on anticoagulation, drug levels or oral absorption are unknown.
• Duplicate 5-amino-1MQ products: Capsules, blends and different salts may contain the same active molecule. Combining them can duplicate exposure.

Product quality risks

• No independent peer-reviewed survey of marketed 5-amino-1MQ products was found. Its mislabeling and contamination rates are unknown.
• FDA documented sterility failures at a facility making this compound. Its endotoxin-positive vial was NAD+, not 5-amino-1MQ.
• A user suspected a wrong ingredient after marked urination; no lab result confirmed a diuretic or counterfeit product.
• An HPLC purity percentage alone does not establish identity, milligrams per vial, sterility or freedom from bacterial toxins.

What to expect

Efficacy evidence is preclinical. One mixed-drug human harm vignette; no human dosing, PK or efficacy trials found.

Key studies

• Obese mice: 11 days: Weight and fat-pad mass fell in mice without a clear fall in food intake. (source)
• Aged mice after muscle injury: An injury model in old mice showed better muscle regeneration. (source)
• Rat absorption and clearance: Oral absorption was measurable in rats, not established in people. (source)
• Diet switch plus NNMT blockade: The combination outperformed diet change alone in mice. (source)
• Mouse microbiome after diet switch: The microbiome pattern differed after combined diet change and NNMT blockade. (source)
• Aged female mice with exercise: Grip strength improved, but other muscle measures did not uniformly improve. (source)

5-amino-1MQ FAQ

• Is 5-amino-1MQ FDA-approved? No FDA-approved product or label found. January 20, 2026 warning letter names 503B ineligibility; no compound-specific PCAC vote was found.
• How do people take it? By mouth, twice daily; 50 mg total per day. About 1 month. Source: reported by users, not an established dose.
• What's the difference between 5-amino-1MQ and Tirzepatide? 5-amino-1MQ: an experimental NNMT blocker with animal findings, no human dosing trials and uncertain risks. Tirzepatide: a weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects. Why people pair them: users add it for energy or to overcome a weight-loss stall.
• Can I take it with Tirzepatide? Users add it for energy or to overcome a weight-loss stall. No human combination trial was found; benefits cannot be separated from diet or other drugs. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Class-rule inference for an unapproved pharmacological molecule. It is not named; no compound-specific WADA ruling was found.
• How long does a mixed vial last? Community advice says refrigerate and protect from light. Potency, sterility and a safe use-by date after mixing are unknown.